Biosion Secures Over RMB 100 Million in Series B Financing to Accelerate Global Innovative Drug Pipeline

VCBeat has learned that Biosion, a global biotechnology company with independent R&D capabilities, announced today the completion of its Series B financing round, exceeding RMB 100 million. The round was led by GF Xinde, with participation from Fangsheng Fund, Yida Capital, and Suxin Venture Capital. Dr. Li Chen from GF Xinde will join the Board of Directors of Biosion.

“We are deeply honored to have earned the trust and support of our investment partners in the biopharmaceutical sector.”Dr. Chen Mingjiu, Founder, Chairman, and CEO of Biosionstated, “We appreciate the industry’s recognition of Biosion’s ‘In Global For Global’ operating model. We will continue to build a world-class team, enhance the international competitiveness of our technology platform, and expand the outcomes of our global collaborations, thereby accelerating the expansion of our innovative drug pipeline and delivering new breakthrough therapies to patients worldwide.”

“Under the current industrial ecosystem, Biosion’s completion of this financing round not only demonstrates the clinical potential of our drug pipeline, but also reflects industry recognition of our globalized team and business development capabilities.”Dr. Ye Xinliang, Director, Chief Strategy Officer, and Head of Business Development for China at Biosion“Biosion continues to explore its global development strategy and has, to date, entered into global co-development and out-licensing partnerships with renowned pharmaceutical companies both in China and abroad, including Chia Tai Tianqing and ImmunoGen, with a total value exceeding $1 billion. We believe that we can create greater value for investors, partners, and patients worldwide in the future.”

“We are pleased to support the advancement of Biosion’s innovative drug R&D pipeline. Biosion boasts an internationally caliber management team, industry-leading technology platforms, and a distinctive, diversified product pipeline. We believe that, empowered by its antibody technology platform and global development model, Biosion will be able to develop breakthrough innovative biologics more efficiently, thereby benefiting a broad patient population.”Dr. Li Chen, GF Xindestated, “We look forward to working hand in hand with Biosion’s global leadership team to help drive the continued success of the company’s global strategy.”

Biosion is a global biotechnology company with independent R&D capabilities, dedicated to developing innovative therapies using its proprietary antibody technology platforms to benefit patients in the treatment of immune and oncological diseases. Founded in 2017, Biosion has established a pipeline of innovative drug candidates through its internal proprietary H³ (High-throughput, High-content, High-efficiency) antibody discovery platform, SynTracer™ ADC antibody internalization screening platform, and Flexibody™ bispecific antibody technology platform. Its self-developed product BSI-045B (an anti-TSLP monoclonal antibody) has entered Phase II clinical trials in China and is scheduled to initiate global Phase II clinical trials for multiple indications, including atopic dermatitis, in the United States in early 2023. Additionally, several other in-house and collaborative pipeline programs have entered clinical stages in both China and the United States. Biosion has branches in China, the United States, and Australia. For more information about the company and its pipeline, please visitwww.biosion.com。

GF Xinde Investment Management Co., Ltd. was established in December 2008 as a wholly-owned private equity fund subsidiary of GF Securities Co., Ltd. (Stock Code: 000776), ranking among the top broker-backed private equity investment subsidiaries in China. Leveraging its superior fund management capabilities, excellent investment research expertise, comprehensive project management skills, and rigorous and pragmatic compliance and risk control measures, GF Xinde has become a preferred capital allocation choice for numerous high-quality investors. Upholding the values of vision, integrity, and collaboration, the company identifies high-quality projects through in-depth industry research. Furthermore, by leveraging the comprehensive advantages of the GF Securities Financial Group and its own strategic management capabilities, GF Xinde provides all-around value-added services to portfolio companies, enhancing their investment value and generating greater returns for investors, thereby achieving a win-win outcome for the company, investors, and portfolio companies. GF Xinde has consistently ranked among the top three in Zero2IPO’s rankings of broker-backed private equity fund managers. Currently, the funds raised and managed by the company span multiple sectors, including healthcare, consumption upgrades, industrial innovation and upgrading, and TMT, covering various investment categories such as private equity (PE), venture capital (VC), and mergers and acquisitions (M&A).

Established in 2009, Fangsheng Equity Investment Fund adopts a “fund of funds + direct investment” approach to achieve diversified global asset allocation. Guided by the principles of value investing and shared-value investment, and committed to promoting the physical and mental well-being of the public, Fangsheng Fund focuses on sectors including biopharmaceuticals, artificial intelligence, sustainable consumption, and digital technology. Since its inception, the firm has invested in nearly 100 outstanding domestic and international enterprises and more than 20 domestic and international funds, with assets under management exceeding RMB 10 billion.

Addor Capital was established through a mixed-ownership reform within the Jiangsu High-Tech Investment Group, a well-established and renowned venture capital firm. Ranking among the industry leaders in terms of industry research capabilities, assets under management, and investment specialization, Addor Capital is one of the most influential venture capital institutions in China. Advocating for full-industry-chain investment, Addor Capital’s fund products cover enterprises at the angel, start-up, growth, and mature stages. Its investment sectors include clean technology, healthcare, new materials, advanced manufacturing, consumer services, cultural industries, and TMT. Through its “Jianghai Plan” and “Star-Studded Network Plan,” the company jointly promotes investment initiatives across China and within the Jiangsu region. It has set up management companies or regional offices in Beijing, Shanghai, Guangdong, Shandong, Zhejiang, Fujian, Anhui, as well as in Southern, Central, and Northern Jiangsu and other developed cities and districts/counties, providing professional and tailored capital market services to innovative and entrepreneurial enterprises.

Suxin Venture Capital is a wholly-owned subsidiary of Suzhou Trust Co., Ltd. It was approved for establishment by the China Banking Regulatory Commission on August 2, 2011, and is a qualified licensed institution registered with the Asset Management Association of China. Focusing on high-quality enterprises in Suzhou and the Yangtze River Delta region, Suxin Venture Capital strategically prioritizes the healthcare and wellness sector. Targeting unmet clinical needs and leveraging advances in biological science and applied technologies, the firm invests in new drug development and import substitution of high-end medical devices in major disease areas such as oncology, cardiovascular diseases, and metabolic disorders.